Adocia S.A. – Advancing Mealtime Insulin Therapy: Phase 3 Results for BC Lispro in Type 2 Diabetes
| DATE: | June 16, 2026 |
|---|---|
| TIME: | 10:00 AM EDT |
| LOCATION: | Virtual |
About The Event
Join Adocia for a virtual key opinion leader (KOL) event featuring Tim Heise, MD (Profil, Neuss, Germany), who will join company management, Olivier Soula, CEO and You-Ping Chan, Head of R&D, to review Phase 3 results of the Company’s BioChaperone® Lispro (BC Lispro) on Type 2 Diabetes in China.
The event will address the following topics:
- Introduction to Adocia’s proprietary BioChaperone® technology platform, by You-Ping Chan
- Current mealtime insulin treatment paradigm for Diabetes and limitations by Tim Heise
- Ultra-Rapid insulin BC Lispro Phase 3 data on Type 2 Diabetes by Tim Heise
- Next steps and potential value creation by Olivier Soula
A live question and answer session will follow the formal presentations.